jerome Honnorat

List of Publications by Year in descending order

278 papers	19,691 citations	13865 67 h-index	14759 127 g-index
294 all docs	294 docs citations	294 times ranked	16269 citing authors

#	Article	IF	Citations
1	Paraneoplastic encephalitis: clinically based approach on diagnosis and management. Postgraduate Medical Journal, 2023, 99, 669-678.	1.8	4
2	Paraneoplastic neurological syndromes: a practical approach to diagnosis and management. Practical Neurology, 2022, 22, 19-31.	1.1	38
3	How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update. Journal of Neurology, 2022, 269, 1701-1714.	3.6	14
4	Immune-Related Cerebellar Ataxia: A Rare Adverse Effect of Checkpoint Inhibitor Therapy. Journal of NeuroImmune Pharmacology, 2022, 17, 377-379.	4.1	7
5	Molecular profile to guide personalized medicine in adult patients with primary brain tumors: results from the ProfiLER trial. Medical Oncology, 2022, 39, 4.	2.5	3
6	Novelties in Autoimmune and Paraneoplastic Cerebellar Ataxias: Twenty Years of Progresses. Cerebellum, 2022, 21, 573-591.	2.5	17
7	Human Leukocyte Antigen Association Study Reveals DRB1*04:02 Effects Additional to DRB1*07:01 in Anti-LGI1 Encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	13
8	The Clinical Concept of LTDpathy: Is Dysregulated LTD Responsible for Prodromal Cerebellar Symptoms?. Brain Sciences, 2022, 12, 303.	2.3	2
9	Gyriform infiltration as imaging biomarker for molecular glioblastomas. Journal of Neuro-Oncology, 2022, 157, 511-521.	2.9	9
10	Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro-Oncology, 2022, 24, 1935-1949.	1.2	165
11	Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yoâ€“Associated Paraneoplastic Cerebellar Degeneration. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	14
12	Cranial Nerve Disorders Associated With Immune Checkpoint Inhibitors. Neurology, 2021, 96, e866-e875.	1.1	44
13	Relationship Between Serum NMDA Receptor Antibodies and Response to Antipsychotic Treatment in First-Episode Psychosis. Biological Psychiatry, 2021, 90, 9-15.	1.3	14
14	Cerebellar long-term depression and auto-immune target of auto-antibodies: the concept of LTDpathies. Molecular Biomedicine, 2021, 2, 2.	4.4	6
15	Immunopathogenesis and proposed clinical score for identifying Kelch-like protein-11 encephalitis. Brain Communications, 2021, 3, fcab185.	3.3	28
16	Familial autoimmunity in neurological patients with GAD65 antibodies: an interview-based study. Journal of Neurology, 2021, 268, 2515-2522.	3.6	4
17	Recurrent seizures of autoimmune origin: emerging phenotypes. Journal of Neurology, 2021, 268, 3000-3010.	3.6	2
18	LTDpathies: a Novel Clinical Concept. Cerebellum, 2021, , 1.	2.5	8

#	ARTICLE	IF	CITATIONS
19	Unclear association between COVID-19 and Guillain-BarrÃ© syndrome. Brain, 2021, 144, e45-e45.	7.6	9
20	Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	43
21	Neurologic Adverse Events of Immune Checkpoint Inhibitors. Neurology, 2021, 96, 754-766.	1.1	109
22	Targeting the Urotensin II/UT G Protein-Coupled Receptor to Counteract Angiogenesis and Mesenchymal Hypoxia/Necrosis in Glioblastoma. Frontiers in Cell and Developmental Biology, 2021, 9, 652544.	3.7	6
23	Distinctive clinical presentation and pathogenic specificities of anti-AK5 encephalitis. Brain, 2021, 144, 2709-2721.	7.6	23
24	Intracranial nonâ€‘myxoid angiomatoid fibrous histiocytoma with EWSR1â€‘CREB1 transcript fusion treated with doxorubicin: A case report. Molecular and Clinical Oncology, 2021, 15, 131.	1.0	5
25	Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	313
26	Cerebrospinal Fluid IL-17A Could Predict Acute Disease Severity in Non-NMDA-Receptor Autoimmune Encephalitis. Frontiers in Immunology, 2021, 12, 673021.	4.8	14
27	Encephalitis with Autoantibodies against the Glutamate Kainate Receptors <scp>GluK2</scp>. Annals of Neurology, 2021, 90, 101-117.	5.3	26
28	Missense variants in DPYSL5 cause a neurodevelopmental disorder with corpus callosum agenesis and cerebellar abnormalities. American Journal of Human Genetics, 2021, 108, 951-961.	6.2	26
29	Argonaute Autoantibodies as Biomarkers in Autoimmune Neurologic Diseases. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	15
30	Abdominal Segmental Myoclonus Mimicking Belly Dancer Dyskinesias in <scp>CASPR2</scp> Antibody Encephalomyelitis. Movement Disorders Clinical Practice, 2021, 8, 1260-1262.	1.5	2
31	Role of LGI1 protein in synaptic transmission: From physiology to pathology. Neurobiology of Disease, 2021, 160, 105537.	4.4	15
32	Current Status of Biomarkers in Anti-N-Methyl-D-Aspartate Receptor Encephalitis. International Journal of Molecular Sciences, 2021, 22, 13127.	4.1	20
33	Epidemiology of paraneoplastic neurological syndromes: a population-based study. Journal of Neurology, 2020, 267, 26-35.	3.6	103
34	Alterations of cerebral microcirculation in peritumoral edema: feasibility of in vivo sidestream dark-field imaging in intracranial meningiomas. Neuro-Oncology Advances, 2020, 2, vdaa108.	0.7	4
35	Psychiatric symptoms in anti glutamic acid decarboxylase associated limbic encephalitis in adults: a systematic review. Neuroscience and Biobehavioral Reviews, 2020, 119, 128-137.	6.1	8
36	Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1076-1084.	1.9	53

#	ARTICLE	IF	CITATIONS
37	Fundamental Mechanisms of Autoantibody-Induced Impairments on Ion Channels and Synapses in Immune-Mediated Cerebellar Ataxias. International Journal of Molecular Sciences, 2020, 21, 4936.	4.1	19
38	Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis. Neurology, 2020, 95, e3012-e3025.	1.1	60
39	Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	74
40	Value of Onconeural Antibodies in Checkpoint Inhibitorâ€Related Toxicities. Annals of Neurology, 2020, 88, 199-200.	5.3	9
41	Anti-Hu-associated paraneoplastic syndromes triggered by immune-checkpoint inhibitor treatment. Journal of Neurology, 2020, 267, 2154-2156.	3.6	18
42	Primary DQ effect in the association between HLA and neurological syndromes with anti-GAD65 antibodies. Journal of Neurology, 2020, 267, 1906-1911.	3.6	18
43	Transient Neurological Symptoms Preceding Cerebellar Ataxia with Glutamic Acid Decarboxylase Antibodies. Cerebellum, 2020, 19, 715-721.	2.5	9
44	Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections, and checkpoint inhibitors. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642093279.	3.5	57
45	Associations between HLA and autoimmune neurological diseases with autoantibodies. Autoimmunity Highlights, 2020, 11, 2.	3.9	63
46	Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	58
47	Mild Encephalitis/Encephalopathy with reversible splenial lesion syndrome: An unusual presentation of anti-GFAP astrocytopathy. European Journal of Paediatric Neurology, 2020, 26, 89-91.	1.6	21
48	Long-term outcomes in temporal lobe epilepsy with glutamate decarboxylase antibodies. Journal of Neurology, 2020, 267, 2083-2089.	3.6	28
49	Diagnostic Criteria for Primary Autoimmune Cerebellar Ataxiaâ€"Guidelines from an International Task Force on Immune-Mediated Cerebellar Ataxias. Cerebellum, 2020, 19, 605-610.	2.5	60
50	Central nervous system complications associated with immune checkpoint inhibitors. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 772-778.	1.9	92
51	Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	74
52	Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	6.0	129
53	Fatal Anti-Ma2 Encephalitis Related to Treatment of Malignant Pleural Mesothelioma With aÂCombination of Anti-Programmed Death 1 and Antiâ€'Cytotoxic T-Lymphocyte Associated Protein 4 Antibodies. Journal of Thoracic Oncology, 2019, 14, e174-e176.	1.1	2
54	Seizure specificities in patients with antibodyâ€mediated autoimmune encephalitis. Epilepsia, 2019, 60, 1508-1525.	5.1	57

#	ARTICLE	IF	CITATIONS
55	Successful Management of Antiâ€mGluR1 Encephalitis with Immunosuppressive Treatment: Dengue Virus as a Trigger?. Movement Disorders Clinical Practice, 2019, 6, 727-728.	1.5	3
56	Stroke-Like Presentation of Paraneoplastic Cerebellar Degeneration: a Single-Center Experience and Review of the Literature. Cerebellum, 2019, 18, 976-982.	2.5	20
57	Impact of anti-CASPR2 autoantibodies from patients with autoimmune encephalitis on CASPR2/TAG-1 interaction and Kv1 expression. Journal of Autoimmunity, 2019, 103, 102284.	6.5	20
58	Immunopathological characterization of ovarian teratomas associated with anti-N-methyl-D-aspartate receptor encephalitis. Acta Neuropathologica Communications, 2019, 7, 38.	5.2	62
59	Reversible myoclonusâ€ataxia encephalitis related to antiâ€mGLUR1 autoantibodies. Movement Disorders, 2019, 34, 438-439.	3.9	7
60	Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study. , 2019, 7, 337.		75
61	Nonparaneoplastic autoimmune cerebellar ataxias. Current Opinion in Neurology, 2019, 32, 484-492.	3.6	23
62	Forecasting outcomes in anti-NMDAR encephalitis. Neurology, 2019, 92, 119-120.	1.1	1
63	Isolated seizures are a common early feature of paraneoplastic anti-GABAB receptor encephalitis. Journal of Neurology, 2019, 266, 195-206.	3.6	58
64	Structural mapping of hot spots within human CASPR2 discoidin domain for autoantibody recognition. Journal of Autoimmunity, 2019, 96, 168-177.	6.5	3
65	TRIM9 and TRIM67 Are New Targets in Paraneoplastic Cerebellar Degeneration. Cerebellum, 2019, 18, 245-254.	2.5	44
66	Motor neuron involvement in anti-Ma2-associated paraneoplastic neurological syndrome. Journal of Neurology, 2019, 266, 398-410.	3.6	31
67	GAD65â€Ab encephalitis and subtle focal status epilepticus. Epileptic Disorders, 2019, 21, 437-442.	1.3	4
68	Paraneoplastic Neurological Syndromes. Contemporary Clinical Neuroscience, 2019, , 439-485.	0.3	3
69	Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG). Oncologist, 2018, 23, 524.	3.7	30
70	Glioblastoma as differential diagnosis of autoimmune encephalitis. Journal of Neurology, 2018, 265, 669-677.	3.6	30
71	Multiplex family with GAD65-Abs neurologic syndromes. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e416.	6.0	16
72	Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma. JAMA Oncology, 2018, 4, 495.	7.1	135

#	ARTICLE	IF	CITATIONS
73	Complex HLA association in paraneoplastic cerebellar ataxia with anti-Yo antibodies. Journal of Neuroimmunology, 2018, 315, 28-32.	2.3	17
74	Effect of thymectomy on refractory autoimmune status epilepticus. Journal of Neuroimmunology, 2018, 317, 90-94.	2.3	13
75	Initial clinical presentation of young children with N-methyl- d -aspartate receptor encephalitis. European Journal of Paediatric Neurology, 2018, 22, 404-411.	1.6	26
76	Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration. Acta Neuropathologica, 2018, 135, 569-579.	7.7	73
77	Molecular Pathogenicity of Anti-NMDA Receptor Autoantibody From Patients With First-Episode Psychosis. American Journal of Psychiatry, 2018, 175, 382-383.	7.2	9
78	Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 789-792.	1.9	41
79	Transcriptional regulation of CRMP5 controls neurite outgrowth through Sox5. Cellular and Molecular Life Sciences, 2018, 75, 67-79.	5.4	16
80	Opposing Morphogenetic Defects on Dendrites and Mossy Fibers of Dentate Granular Neurons in CRMP3-Deficient Mice. Brain Sciences, 2018, 8, 196.	2.3	6
81	Malignant tumors in autoimmune encephalitis with anti-NMDA receptor antibodies. Journal of Neurology, 2018, 265, 2190-2200.	3.6	64
82	Contactinâ€associated proteinâ€like 2, a protein of the neurexin family involved in several human diseases. European Journal of Neuroscience, 2018, 48, 1906-1923.	2.6	56
83	Immune-mediated ataxias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 155, 313-332.	1.8	38
84	Transcriptomic immune profiling of ovarian cancers in paraneoplastic cerebellar degeneration associated with anti-Yo antibodies. British Journal of Cancer, 2018, 119, 105-113.	6.4	15
85	Characteristics in limbic encephalitis with antiâ€“adenylate kinase 5 autoantibodies. Neurology, 2017, 88, 514-524.	1.1	49
86	Netrin-1 receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravis. Neurology, 2017, 88, 1235-1242.	1.1	28
87	Methionine tumor starvation by erythrocyteâ€encapsulated methionine gammaâ€lyase activity controlled with per os vitamin B6. Cancer Medicine, 2017, 6, 1437-1452.	2.8	28
88	Analysis of temozolomide resistance in lowâ€grade gliomas using a mechanistic mathematical model. Fundamental and Clinical Pharmacology, 2017, 31, 347-358.	1.9	24
89	Autoimmune episodic ataxia in patients with anti-CASPR2 antibody-associated encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e371.	6.0	64
90	Cell- and Single Molecule-Based Methods to Detect Anti- N -Methyl-D-Aspartate Receptor Autoantibodies in Patients With First-Episode Psychosis From the OPTiMiSE Project. Biological Psychiatry, 2017, 82, 766-772.	1.3	67

#	ARTICLE	IF	CITATIONS
91	Antiâ€“N-Methyl-<scp>d</scp>-Aspartate Receptor Encephalitis in Adult Patients Requiring Intensive Care. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 491-499.	5.6	103
92	Ephrin-B3 supports glioblastoma growth by inhibiting apoptosis induced by the dependence receptor EphA4. Oncotarget, 2017, 8, 23750-23759.	1.8	21
93	Autoimmune encephalitis in psychiatric institutions: current perspectives. Neuropsychiatric Disease and Treatment, 2016, Volume 12, 2775-2787.	2.2	52
94	Syk kinases are required for spinal commissural axon repulsion at the midline via ephrin/Eph pathway. Development (Cambridge), 2016, 143, 2183-93.	2.5	8
95	Neuroleptic intolerance in patients with anti-NMDAR encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e280.	6.0	139
96	Characterization of a Subtype of Autoimmune Encephalitis With Antiâ€“Contactin-Associated Protein-like 2 Antibodies in the Cerebrospinal Fluid, Prominent Limbic Symptoms, and Seizures. JAMA Neurology, 2016, 73, 1115.	9.0	155
97	Treatment of Progressive Multifocal Leukoencephalopathy With Mirtazapine. Clinical Drug Investigation, 2016, 36, 783-789.	2.2	43
98	Neuronal central nervous system syndromes probably mediated by autoantibodies. European Journal of Neuroscience, 2016, 43, 1535-1552.	2.6	21
99	Characteristics of gliomas in patients with somatic IDH mosaicism. Acta Neuropathologica Communications, 2016, 4, 31.	5.2	29
100	Anti-NMDA-R encephalitis: Should we consider extreme delta brush as electrical status epilepticus?. Neurophysiologie Clinique, 2016, 46, 17-25.	2.2	32
101	Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors. Molecular Cancer Therapeutics, 2016, 15, 1261-1270.	4.1	19
102	New Findings in Adult Opsoclonus-Myoclonus Syndrome. JAMA Neurology, 2016, 73, 381.	9.0	7
103	A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurology, The, 2016, 15, 391-404.	10.2	2,782
104	Pseudotumoral presentation of cerebral amyloid angiopathyâ€“related inflammation. Neurology, 2016, 86, 912-919.	1.1	33
105	Cyclophosphamide-responsive Lgi1-related limbic encephalitis with basal ganglia hypermetabolism. Acta Neurologica Belgica, 2016, 116, 379-381.	1.1	2
106	Motor cortex and hippocampus are the two main cortical targets in LGI1-antibody encephalitis. Brain, 2016, 139, 1079-1093.	7.6	157
107	Computer-aided Therapeutics in Treating Autoimmune Encephalitisâ€”Reply. JAMA Neurology, 2016, 73, 128.	9.0	0
108	Consensus Paper: Neuroimmune Mechanisms of Cerebellar Ataxias. Cerebellum, 2016, 15, 213-232.	2.5	142

#	ARTICLE	IF	CITATIONS
109	Neuronal networks in mental diseases and neuropathic pain: Beyond brain derived neurotrophic factor and collapsin response mediator proteins. World Journal of Psychiatry, 2016, 6, 18.	2.7	10
110	Cerebellar vermis hypermetabolism in opsoclonus myoclonus without onconeural antibodies. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e168.	6.0	4
111	Guidelines for treatment of immune-mediated cerebellar ataxias. Cerebellum and Ataxias, 2015, 2, 14.	1.9	143
112	Disease-specific monoclonal antibodies targeting glutamate decarboxylase impair GABAergic neurotransmission and affect motor learning and behavioral functions. Frontiers in Behavioral Neuroscience, 2015, 9, 78.	2.0	59
113	Inhibitory axons are targeted in hippocampal cell culture by anti-Caspr2 autoantibodies associated with limbic encephalitis. Frontiers in Cellular Neuroscience, 2015, 9, 265.	3.7	54
114	Increasing the Time Interval between PCV Chemotherapy Cycles as a Strategy to Improve Duration of Response in Low-Grade Gliomas: Results from a Model-Based Clinical Trial Simulation. Computational and Mathematical Methods in Medicine, 2015, 2015, 1-7.	1.3	9
115	Treatment and outcome of children and adolescents with N-methyl-d-aspartate receptor encephalitis. Journal of Neurology, 2015, 262, 1859-1866.	3.6	105
116	CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma. Neuro-Oncology, 2015, 17, 1497-1503.	1.2	52
117	Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma. JAMA - Journal of the American Medical Association, 2015, 314, 2535.	7.4	982
118	Peripheral small fiber dysfunction and neuropathic pain in patients with Morvan syndrome. Neurology, 2015, 85, 2076-2078.	1.1	28
119	CSF IgA NMDAR antibodies are potential biomarkers for teratomas in anti-NMDAR encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e166.	6.0	18
120	Antifibroblast growth factor receptor 3 antibodies identify a subgroup of patients with sensory neuropathy. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1347-1355.	1.9	48
121	A mouse model of autoimmune encephalitis. Brain, 2015, 138, 5-8.	7.6	3
122	Immunoglobulin <scp>G</scp> antibodies to the <scp>N</scp>â€Methylâ€<scp>D</scp>â€aspartate receptor are distinct from immunoglobulin <scp>A</scp> and immunoglobulin <scp>M</scp> responses. Annals of Neurology, 2015, 77, 183-183.	5.3	20
123	CRMP5 Controls Glioblastoma Cell Proliferation and Survival through Notch-Dependent Signaling. Cancer Research, 2015, 75, 3519-3528.	0.9	35
124	Autoimmune channelopathies in paraneoplastic neurological syndromes. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 2665-2676.	2.6	25
125	The workflow from post-mortem human brain sampling to cell microdissection: a Brain Net Europe study. Journal of Neural Transmission, 2015, 122, 975-991.	2.8	8
126	Prediction of anaplastic transformation in low-grade oligodendrogliomas based on magnetic resonance spectroscopy and 1p/19q codeletion status. Journal of Neuro-Oncology, 2015, 122, 529-537.	2.9	12

#	ARTICLE	IF	CITATIONS
127	Telomerase inhibition improves tumor response to radiotherapy in a murine orthotopic model of human glioblastoma. Molecular Cancer, 2015, 14, 134.	19.2	25
128	Paraneoplastic subacute lower motor neuron syndrome associated with solid cancer. Journal of the Neurological Sciences, 2015, 358, 413-416.	0.6	15
129	Clinical Spectrum of Encephalitis Associated With Antibodies Against the Î±-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor. JAMA Neurology, 2015, 72, 1163.	9.0	123
130	Standardized test for anti-Tr/DNER in patients with paraneoplastic cerebellar degeneration. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e68.	6.0	25
131	Intrathecal treatment of antiâ€Nâ€Methylâ€<scp>d</scp>â€aspartate receptor encephalitis in children. Developmental Medicine and Child Neurology, 2015, 57, 95-99.	2.1	48
132	Tumor treating fields (TTFields): A novel treatment modality added to standard chemo- and radiotherapy in newly diagnosed glioblastomaâ€"First report of the full dataset of the EF14 randomized phase III trial.. Journal of Clinical Oncology, 2015, 33, 2000-2000.	1.6	16
133	Impact of bevacizumab added to temozolomide-chemoradiation on time to health-related quality of life deterioration in unresectable glioblastoma: Results of a phase II randomized clinical trial.. Journal of Clinical Oncology, 2015, 33, 2018-2018.	1.6	0
134	Collapsin Response Mediator Protein 5 (CRMP5) Induces Mitophagy, Thereby Regulating Mitochondrion Numbers in Dendrites. Journal of Biological Chemistry, 2014, 289, 2261-2276.	3.4	17
135	An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent Glioblastomas. BioMed Research International, 2014, 2014, 1-8.	1.9	8
136	Seronegative paraneoplastic cerebellar degeneration: the <scp>PNS E</scp>uronetwork experience. European Journal of Neurology, 2014, 21, 731-735.	3.3	46
137	Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. Neuro-Oncology, 2014, 16, 662-670.	1.2	59
138	Early-onset immunotherapy by intravenous immunoglobulin and corticosteroids in well characterized onconeural-antibody-positive paraneoplastic neurological syndrome. Clinical and Experimental Immunology, 2014, 178, 127-129.	2.6	5
139	Potential side effect of propofol and sevoflurane for anesthesia of anti-NMDA-R encephalitis. BMC Anesthesiology, 2014, 14, 5.	1.8	25
140	Surface dynamics of GluN2B-NMDA receptors controls plasticity of maturing glutamate synapses. EMBO Journal, 2014, 33, 842-861.	7.8	101
141	Paraneoplastic disorders of the central and peripheral nervous systems. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 121, 1159-1179.	1.8	31
142	Impact of meriolins, a new class of cyclin-dependent kinase inhibitors, on malignant glioma proliferation and neo-angiogenesis. Neuro-Oncology, 2014, 16, 1484-1498.	1.2	23
143	Collapsin responseâ€mediator protein 5 (CRMP5) phosphorylation at threonine 516 regulates neurite outgrowth inhibition. European Journal of Neuroscience, 2014, 40, 3010-3020.	2.6	19
144	Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis. Neurology, 2014, 82, 556-563.	1.1	202

#	ARTICLE	IF	CITATIONS
145	Therapeutic approaches in antibody-associated central nervous system pathologies. Revue Neurologique, 2014, 170, 587-594.	1.5	8
146	Autoimmune N-methyl-D-aspartate receptor encephalitis is a differential diagnosis of infectious encephalitis. Journal of Infection, 2014, 68, 419-425.	3.3	19
147	Monoclonal antibodies to 65kDa glutamate decarboxylase induce epitope specific effects on motor and cognitive functions in rats. Orphanet Journal of Rare Diseases, 2013, 8, 82.	2.7	46
148	Paraneoplastic Neurological Syndromes: General Treatment Overview. Current Treatment Options in Neurology, 2013, 15, 150-168.	1.8	22
149	From anti-GAD to ataxia with ocular motor apraxia type 2: through the looking glass. Journal of Neurology, 2013, 260, 1158-1159.	3.6	1
150	Mapping CRMP3 domains involved in dendrite morphogenesis and voltage-gated calcium channel regulation. Journal of Cell Science, 2013, 126, 4262-73.	2.0	21
151	Extensive myelitis associated with anti-NMDA receptor antibodies. BMC Neurology, 2013, 13, 211.	1.8	21
152	Autoimmune encephalopathies. Neurology, 2013, 81, 1482-1483.	1.1	2
153	Early electro-clinical features may contribute to diagnosis of the anti-NMDA receptor encephalitis in children. Clinical Neurophysiology, 2013, 124, 2354-2361.	1.5	69
154	Identification of a new CRMP5 isoform present in the nucleus of cancer cells and enhancing their proliferation. Experimental Cell Research, 2013, 319, 588-599.	2.6	11
155	Telomere Profiling: Toward Glioblastoma Personalized Medicine. Molecular Neurobiology, 2013, 47, 64-76.	4.0	31
156	Evidence of timeâ€dependent prognostic factors predicting early death but not longâ€term outcome in primary CNS lymphoma: a study of 91 patients. Hematological Oncology, 2013, 31, 57-64.	1.7	19
157	Aquaporin-4 antibodyâ€“negative neuromyelitis optica. Neurology, 2013, 80, 2194-2200.	1.1	157
158	Autoimmune limbic encephalopathy and anti-Hu antibodies in children without cancer. Neurology, 2013, 80, 2226-2232.	1.1	68
159	Mapping and kinetics of microglia/neuron cell-to-cell contacts in the 6-OHDA murine model of Parkinson's disease. Glia, 2013, 61, 1645-1658.	4.9	35
160	Acuteâ€onset chorea, dystonia, and cardiac fibroelastoma in a child: A paraneoplastic association?. Movement Disorders, 2013, 28, 250-251.	3.9	4
161	Autoantibodies to neurotransmitter receptors and ion channels: from neuromuscular to neuropsychiatric disorders. Frontiers in Genetics, 2013, 4, 181.	2.3	14
162	In Vitro and In Vivo Models of Cerebral Ischemia Show Discrepancy in Therapeutic Effects of M2 Macrophages. PLoS ONE, 2013, 8, e67063.	2.5	43

#	ARTICLE	IF	CITATIONS
163	Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain, 2012, 135, 1606-1621.	7.6	272
164	A Tumor Growth Inhibition Model for Low-Grade Glioma Treated with Chemotherapy or Radiotherapy. Clinical Cancer Research, 2012, 18, 5071-5080.	7.0	103
165	The Collapsin Response Mediator Protein 5 Onconeural Protein Is Expressed in Schwann Cells Under Axonal Signals and Regulates Axonâ€"Schwann Cell Interactions. Journal of Neuropathology and Experimental Neurology, 2012, 71, 298-311.	1.7	20
166	Full recovery of agrypnia associated with anti-Lgi1 antibodies encephalitis under immunomodulatory treatment: A case report with sequential polysomnographic assessment. Sleep Medicine, 2012, 13, 554-556.	1.6	19
167	ATAD3B is a human embryonic stem cell specific mitochondrial protein, re-expressed in cancer cells, that functions as dominant negative for the ubiquitous ATAD3A. Mitochondrion, 2012, 12, 441-448.	3.4	32
168	NovoTTF-100A versus physicianâ€™s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality. European Journal of Cancer, 2012, 48, 2192-2202.	2.8	661
169	Phosphorylation of CRMP2 (Collapsin Response Mediator Protein 2) Is Involved in Proper Dendritic Field Organization. Journal of Neuroscience, 2012, 32, 1360-1365.	3.6	88
170	SNP Array Analysis Reveals Novel Genomic Abnormalities Including Copy Neutral Loss of Heterozygosity in Anaplastic Oligodendrogliomas. PLoS ONE, 2012, 7, e45950.	2.5	25
171	Comparative assessment of 5 methods (methylationâ€specific polymerase chain reaction, methylight,) Tj ETQq1 1 0.784314 rgBT /Over O6â€methylguanineâ€DNAâ€methyltranferase in a series of 100 glioblastoma patients. Cancer, 2012, 118, 4201-4211.	4.1	172
172	Drug Binding Assays do not Reveal Specific Binding of Lacosamide to Collapsin Response Mediator Protein 2 (CRMPâ€2). CNS Neuroscience and Therapeutics, 2012, 18, 493-500.	3.9	33
173	PET follow-up in a case of anti-NMDAR encephalitis: arguments for cingulate limbic encephalitis. Epileptic Disorders, 2012, 14, 90-93.	1.3	12
174	G303V tau mutation presenting with progressive supranuclear palsyâ€"like features. Movement Disorders, 2012, 27, 581-583.	3.9	14
175	Pure monomelic sensory neuronopathy associated with antiâ€yo antibodies. Muscle and Nerve, 2012, 45, 297-298.	2.2	7
176	New targeted therapies in pituitary carcinoma resistant to temozolomide. Pituitary, 2012, 15, 37-43.	2.9	87
177	New concepts in paraneoplastic neurological syndromes. Revue Neurologique, 2011, 167, 729-736.	1.5	20
178	Clinical presentation of immune-mediated cerebellar ataxia. Revue Neurologique, 2011, 167, 408-417.	1.5	23
179	Syk kinase is phosphorylated in specific areas of the developing nervous system. Neuroscience Research, 2011, 70, 172-182.	1.9	9
180	Afferent facilitation of corticomotor responses is increased by IgGs of patients with NMDA-receptor antibodies. Journal of Neurology, 2011, 258, 27-33.	3.6	36

#	ARTICLE	IF	CITATIONS
181	Favorable outcome with bevacizumab after poor outcome with steroids in a patient with temporal lobe and brainstem radiation necrosis. Journal of Neurology, 2011, 258, 328-329.	3.6	28
182	Chorea and related movement disorders of paraneoplastic origin: the PNS EuroNetwork experience. Journal of Neurology, 2011, 258, 2058-2068.	3.6	81
183	Respective implications of glutamate decarboxylase antibodies in stiff person syndrome and cerebellar ataxia. Orphanet Journal of Rare Diseases, 2011, 6, 3.	2.7	75
184	Peri-ictal pseudoprogression in patients with brain tumor. Neuro-Oncology, 2011, 13, 775-782.	1.2	38
185	Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial. Journal of Clinical Oncology, 2011, 29, 3050-3055.	1.6	196
186	VEGF modulates NMDA receptors activity in cerebellar granule cells through Src-family kinases before synapse formation. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 13782-13787.	7.1	41
187	Autoimmune limbic encephalitis. Future Neurology, 2011, 6, 97-111.	0.5	2
188	CRMP5 Regulates Generation and Survival of Newborn Neurons in Olfactory and Hippocampal Neurogenic Areas of the Adult Mouse Brain. PLoS ONE, 2011, 6, e23721.	2.5	29
189	M1-Activated Macrophages Migration, A Marker of Aortic Atheroma Progression. Investigative Radiology, 2010, 45, 262-269.	6.2	9
190	Facial pain as first manifestation of anti-Hu paraneoplastic syndrome. Journal of Headache and Pain, 2010, 11, 355-357.	6.0	13
191	Up-front temozolomide in elderly patients with glioblastoma. Journal of Neuro-Oncology, 2010, 99, 89-94.	2.9	47
192	Predictive value of multimodality MRI using conventional, perfusion, and spectroscopy MR in anaplastic transformation of low-grade oligodendrogliomas. Journal of Neuro-Oncology, 2010, 97, 73-80.	2.9	69
193	Autoimmune limbic encephalitis: an expanding concept. Lancet Neurology, The, 2010, 9, 24-25.	10.2	12
194	Is autoimmune limbic encephalitis a channelopathy?. Lancet Neurology, The, 2010, 9, 753-755.	10.2	4
195	HLA-DQ2+ individuals are susceptible to Hu-Ab associated paraneoplastic neurological syndromes. Journal of Neuroimmunology, 2010, 226, 147-149.	2.3	23
196	Pp IX Silica Nanoparticles Demonstrate Differential Interactions with In Vitro Tumor Cell Lines and In Vivo Mouse Models of Human Cancers. Photochemistry and Photobiology, 2010, 86, 213-222.	2.5	44
197	Expanding Spectrum of Encephalitis With NMDA Receptor Antibodies in Young Children. Journal of Child Neurology, 2010, 25, 742-745.	1.4	68
198	Delayed onset of a second paraneoplastic neurological syndrome in eight patients. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 937-939.	1.9	31

#	ARTICLE	IF	CITATIONS
199	Matrix-Binding Vascular Endothelial Growth Factor (VEGF) Isoforms Guide Granule Cell Migration in the Cerebellum via VEGF Receptor Flk1. Journal of Neuroscience, 2010, 30, 15052-15066.	3.6	75
200	Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro-Oncology, 2010, 12, 1078-1082.	1.2	81
201	Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro-Oncology, 2010, 12, 725-735.	1.2	149
202	Paraneoplastic Neurologic Syndrome in the PNS Euronetwork Database. Archives of Neurology, 2010, 67, 330.	4.5	315
203	Metabotropic Glutamate Receptor Type 1 Autoantibodyâ€“Associated Cerebellitis. Archives of Neurology, 2010, 67, 627-30.	4.5	99
204	Collapsin Response Mediator Protein 4a (CRMP4a) Is Upregulated in Motoneurons of Mutant SOD1 Mice and Can Trigger Motoneuron Axonal Degeneration and Cell Death. Journal of Neuroscience, 2010, 30, 785-796.	3.6	53
205	CRMP5 Interacts with Tubulin to Inhibit Neurite Outgrowth, Thereby Modulating the Function of CRMP2. Journal of Neuroscience, 2010, 30, 10639-10654.	3.6	62
206	NG2-expressing glial precursor cells are a new potential oligodendroglioma cell initiating population in N -ethyl- N -nitrosourea-induced gliomagenesis. Carcinogenesis, 2010, 31, 1718-1725.	2.8	27
207	Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain, 2010, 133, 2578-2591.	7.6	180
208	An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients. Molecular Cancer, 2010, 9, 234.	19.2	37
209	In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: further evidence of synaptic glutamatergic dysfunction. Orphanet Journal of Rare Diseases, 2010, 5, 31.	2.7	102
210	Acute Headache Followed by Focal Neuropsychological Impairment in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL). Journal of Stroke and Cerebrovascular Diseases, 2010, 19, 75-76.	1.6	4
211	Neurologiques. , 2010, , 257-262.		0
212	The pattern and diagnostic criteria of sensory neuronopathy: a case-control study. Brain, 2009, 132, 1723-1733.	7.6	259
213	Early-Stage Investigations of Ultrasmall Superparamagnetic Iron Oxide-Induced Signal Change After Permanent Middle Cerebral Artery Occlusion in Mice. Stroke, 2009, 40, 1834-1841.	2.0	63
214	Phosphorylation of Collapsin Response Mediator Protein 2 on Tyr-479 Regulates CXCL12-induced T Lymphocyte Migration. Journal of Biological Chemistry, 2009, 284, 13265-13276.	3.4	47
215	Altered expression of CRMPs in the brain of bovine spongiform encephalopathy-infected mice during disease progression. Brain Research, 2009, 1261, 1-6.	2.2	7
216	Les syndromes paranÃ©oplasiques neurologiques. Oncologie, 2009, 11, 83-89.	0.7	2

#	ARTICLE	IF	CITATIONS
217	Ipsilateral ptosis as main feature of tuberothalamic artery infarction. Neurological Sciences, 2009, 30, 69-70.	1.9	8
218	Update on paraneoplastic neurological syndromes. Current Opinion in Oncology, 2009, 21, 566-572.	2.4	30
219	Microarray gene expression profiling in meningiomas: Differential expression according to grade or histopathological subtype. International Journal of Oncology, 2009, 35, 1395-407.	3.3	51
220	Recurrent cerebral venous thrombosis revealing paraneoplastic angiitis in Hodgkinâ€™s lymphoma. Journal of Neuro-Oncology, 2008, 89, 195-198.	2.9	12
221	Abnormal expression of truncated CRMP-1 protein in the brain cortex of MPSIIIB mice. Molecular Genetics and Metabolism, 2008, 94, 135-138.	1.1	1
222	Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 80, 412-416.	1.9	217
223	NMO-IgG and Devic's neuromyelitis optica: a French experience. Multiple Sclerosis Journal, 2008, 14, 440-445.	3.0	107
224	CRMP3 is required for hippocampal CA1 dendritic organization and plasticity. FASEB Journal, 2008, 22, 401-409.	0.5	62
225	Processing and Nuclear Localization of CRMP2 during Brain Development Induce Neurite Outgrowth Inhibition. Journal of Biological Chemistry, 2008, 283, 14751-14761.	3.4	46
226	Extensive Expression of Collapsin Response Mediator Protein 5 (CRMP5) is a Specific Marker of High-grade Lung Neuroendocrine Carcinoma. American Journal of Surgical Pathology, 2008, 32, 1699-1708.	3.7	31
227	Cerebrospinal Fluid Dendritic Cells Infiltrate the Brain Parenchyma and Target the Cervical Lymph Nodes under Neuroinflammatory Conditions. PLoS ONE, 2008, 3, e3321.	2.5	73
228	Regulation of Spine Development by Semaphorin3A through Cyclin-Dependent Kinase 5 Phosphorylation of Collapsin Response Mediator Protein 1. Journal of Neuroscience, 2007, 27, 12546-12554.	3.6	105
229	Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: Data from the French-Italian HHT network. Genetics in Medicine, 2007, 9, 14-22.	2.4	196
230	Radiotherapy for Glioblastoma in the Elderly. New England Journal of Medicine, 2007, 356, 1527-1535.	27.0	736
231	MRI Monitoring of Neuroinflammation in Mouse Focal Ischemia. Stroke, 2007, 38, 131-137.	2.0	94
232	USPIO-Enhanced MRI of Neuroinflammation at the Sub-Acute Stage of Ischemic Stroke: Preliminary Data. Cerebrovascular Diseases, 2007, 24, 544-546.	1.7	20
233	Paraneoplastic neurological syndromes. Orphanet Journal of Rare Diseases, 2007, 2, 22.	2.7	252
234	Effects of antiâ€“glutamic acid decarboxylase antibodies associated with neurological diseases. Annals of Neurology, 2007, 61, 544-551.	5.3	218

#	ARTICLE	IF	CITATIONS
235	French brain tumor data bank: Methodology and first results on 10,000 cases. Journal of Neuro-Oncology, 2007, 84, 189-199.	2.9	103
236	Chemotherapy is the cornerstone of the combined surgical treatment of lung cancer with synchronous brain metastases. Lung Cancer, 2006, 53, 51-58.	2.0	40
237	Les syndromes neurologiques paranÃ©oplasiques. Revue De Medecine Interne, 2006, 27, S269-S271.	1.0	1
238	Calpain product of WT-CRMP2 reduces the amount of surface NR2B NMDA receptor subunit. Journal of Neurochemistry, 2006, 98, 1252-1265.	3.9	73
239	Onconeural antibodies are essential to diagnose paraneoplastic neurological syndromes. Acta Neurologica Scandinavica, 2006, 113, 64-68.	2.1	17
240	Transient alterations in granule cell proliferation, apoptosis and migration in postnatal developing cerebellum of CRMP1?/?mice. Genes To Cells, 2006, 11, 1337-1352.	1.2	43
241	Expression of the onconeural CV2/CRMP5 antigen in thymus and thymoma. Journal of Neuroimmunology, 2006, 174, 168-173.	2.3	21
242	Devic's syndrome-like phenotype associated with thymoma and anti-CV2/CRMP5 antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 325-327.	1.9	41
243	IQGAP1 Protein Specifies Amplifying Cancer Cells in Glioblastoma Multiforme. Cancer Research, 2006, 66, 9074-9082.	0.9	50
244	Collapsin Response Mediator Protein 1 Mediates Reelin Signaling in Cortical Neuronal Migration. Journal of Neuroscience, 2006, 26, 13357-13362.	3.6	82
245	Potential Role of Anti-GAD Antibodies in Abnormal Eye Movements. Annals of the New York Academy of Sciences, 2005, 1039, 446-454.	3.8	34
246	Expression of collapsin response mediator proteins 1, 2 and 5 is differentially regulated in newly generated and mature neurons of the adult olfactory system. European Journal of Neuroscience, 2005, 21, 2635-2648.	2.6	38
247	Semaphorin3A signalling is mediated via sequential Cdk5 and GSK3Î² phosphorylation of CRMP2: implication of common phosphorylating mechanism underlying axon guidance and Alzheimer's disease. Genes To Cells, 2005, 10, 165-179.	1.2	377
248	A New Mutation of the Ï„ Gene, G303V, in Early-Onset Familial Progressive Supranuclear Palsy. Archives of Neurology, 2005, 62, 1444.	4.5	86
249	Ethical Issues of Informed Consent in Acute Stroke. Cerebrovascular Diseases, 2005, 19, 65-68.	1.7	43
250	Simultaneous Subarachnoid Hemorrhage and Cerebellar Infarct Revealing Vertebral Artery Aneurysm. Archives of Neurology, 2005, 62, 1158.	4.5	2
251	Anti-GAD Antibodies and Periodic Alternating Nystagmus. Archives of Neurology, 2005, 62, 1300.	4.5	39
252	Early Fibrinogen Degradation Coagulopathy Is Predictive of Parenchymal Hematomas in Cerebral rt-PA Thrombolysis. Stroke, 2004, 35, 1323-1328.	2.0	99

#	ARTICLE	IF	CITATIONS
253	Thrombolysis for Ischemic Stroke in Patients with Old Microbleeds on Pretreatment MRI. Cerebrovascular Diseases, 2004, 17, 238-241.	1.7	113
254	Magnetic Resonance Imaging: Significance of Early Ischemic Changes on Computed Tomography. Cerebrovascular Diseases, 2004, 18, 232-235.	1.7	2
255	Paraneoplastic antibodies detected by isoelectric focusing of cerebrospinal fluid and serum. Journal of Neuroimmunology, 2004, 155, 150-154.	2.3	26
256	Involvement of collapsin response mediator proteins in the neurite extension induced by neurotrophins in dorsal root ganglion neurons. Molecular and Cellular Neurosciences, 2004, 25, 433-443.	2.2	69
257	Advances in paraneoplastic neurological syndromes. Current Opinion in Oncology, 2004, 16, 614-620.	2.4	36
258	Collapsin Response Mediator Proteins (CRMPs): Involvement in Nervous System Development and Adult Neurodegenerative Disorders. Molecular Neurobiology, 2003, 28, 51-64.	4.0	244
259	Myorhythmia associated with Hodgkin?s lymphoma. Journal of Neurology, 2003, 250, 1382-1384.	3.6	15
260	Hypointense Transcerebral Veins at T2â^—-Weighted MRI: A Marker of Hemorrhagic Transformation Risk in Patients Treated with Intravenous Tissue Plasminogen Activator. Journal of Cerebral Blood Flow and Metabolism, 2003, 23, 1362-1370.	4.3	60
261	Factors Influencing Early Admission in a French Stroke Unit. Stroke, 2002, 33, 153-159.	2.0	170
262	Paraneoplastic peripheral neuropathy associated with antiâ€Hu antibodies. Brain, 2002, 125, 166-175.	7.6	240
263	Beware of optic neuritis!. Lancet Neurology, The, 2002, 1, 516-517.	10.2	31
264	Isolation and Expression Pattern of Human Unc-33-Like Phosphoprotein 6/Collapsin Response Mediator Protein 5 (Ulip6/CRMP5): Coexistence with Ulip2/CRMP2 in Sema3A- Sensitive Oligodendrocytes. Journal of Neuroscience, 2001, 21, 7203-7214.	3.6	126
265	Are the ?newly discovered? paraneoplastic anti-collapsin response-mediator protein 5 antibodies simply anti-cv2 antibodies?. Annals of Neurology, 2001, 50, 688-690.	5.3	23
266	Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Annals of Neurology, 2001, 49, 214-221.	5.3	167
267	Redifferentiation therapy in brain tumors: long-lasting complete regression of glioblastomas and an anaplastic astrocytoma under long term 1-alpha-hydroxycholecalciferol. Journal of Neuro-Oncology, 2001, 51, 57-66.	2.9	38
268	Cerebellar Ataxia With Antiâ€“Glutamic Acid Decarboxylase Antibodies. Archives of Neurology, 2001, 58, 225.	4.5	371
269	Anti-CV2 Autoantibodies and Paraneoplastic Neurological Syndromes. Clinical Reviews in Allergy and Immunology, 2000, 19, 51-60.	6.5	40
270	Collapsin response mediator protein-3/unc-33-like protein-4 gene: organization, chromosomal mapping and expression in the developing mouse brain. Gene, 2000, 242, 175-182.	2.2	27

#	ARTICLE	IF	CITATIONS
271	Ulip/CRMP proteins are recognized by autoantibodies in paraneoplastic neurological syndromes. European Journal of Neuroscience, 1999, 11, 4226-4232.	2.6	65
272	Antiamphiphysin Antibodies Are Associated With Various Paraneoplastic Neurological Syndromes and Tumors. Archives of Neurology, 1999, 56, 172.	4.5	152
273	Paraneoplastic Cerebellar Syndrome and Optic Neuritis With Anti-CV2 Antibodies. Archives of Neurology, 1998, 55, 405.	4.5	75
274	POP66, A Paraneoplastic Encephalomyelitis-related Antigen, Is a Marker of Adult Oligodendrocytes. Journal of Neuropathology and Experimental Neurology, 1998, 57, 311-322.	1.7	34
275	Molecular cloning of a new unc-33-like cDNA from rat brain and its relation to paraneoplastic neurological syndromes. Molecular Brain Research, 1997, 46, 329-332.	2.3	22
276	Paraneoplastic opsomyoclonus, cerebellar ataxia and encephalopathy associated with anti-Purkinje cell antibodies. Journal of Neurology, 1997, 244, 333-335.	3.6	13
277	Effects of diabetes type and treatment on zinc status in diabetes mellitus. Biological Trace Element Research, 1992, 32, 311-316.	3.5	28
278	Long-term evolution and prognostic factors of epilepsy in limbic encephalitis with LGI1 antibodies. Journal of Neurology, 0, , .	3.6	8